Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone

被引:160
作者
Choi, Sung-Wook [1 ]
Kim, Jung-Hyun [1 ]
机构
[1] Yonsei Univ, Dept Chem Engn, Nanosphere Proc & Technol Lab, Seoul 120749, South Korea
关键词
bone-targeted drug delivery; dialysis method; PLGA nanoparticles; alendronate; mPEG-PLGA block copolymer; CHEMICAL-MODIFICATION; POLY(L-LACTIC ACID); RELEASE; COPOLYMERS; GLYCOL); SYSTEM; CORE;
D O I
10.1016/j.jconrel.2007.06.003
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles, modified with both alendronate and polyethylene glycol (PEG), were prepared by dialysis method without additional surfactant to evaluate the potency of the bone-targeted drug delivery. Alendronate, a targeting moiety that has a strong affinity for bone, was conjugated to PLGA polymer via carbodiimide chemistry. Monomethoxy PEG(mPEG)-PLGA block copolymers with different molecular weights of mPEG (M 550, 750, and 2000) were synthesized and used for a hydrophilic layer on the surface of the nanoparticles to avoid reticuloendothelial system (RES). The surface-modified PLGA nanoparticles with various ratios of alendronate and mPEG densities on their surface were evaluated by adsorption study onto hydroxyapatite (HA). It was confirmed that alendronate-modified nanoparticles had a strong and specific adsorption to HA. The amount of nanoparticles absorbed onto HA tended to be smaller when the content of alendronate was decreased and the large block length of mPEG was found to reduce the potency of alendronate. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 32 条
[1]   MICELLIZATION OF POLY(ETHYLENE OXIDE)-POLY(PROPYLENE OXIDE)-POLY(ETHYLENE OXIDE) TRIBLOCK COPOLYMERS IN AQUEOUS-SOLUTIONS - THERMODYNAMICS OF COPOLYMER ASSOCIATION [J].
ALEXANDRIDIS, P ;
HOLZWARTH, JF ;
HATTON, TA .
MACROMOLECULES, 1994, 27 (09) :2414-2425
[2]   Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene [J].
Cho, CS ;
Cho, KY ;
Park, IK ;
Kim, SH ;
Sasagawa, T ;
Uchiyama, M ;
Akaike, T .
JOURNAL OF CONTROLLED RELEASE, 2001, 77 (1-2) :7-15
[3]   THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN [J].
COLDITZ, GA ;
HANKINSON, SE ;
HUNTER, DJ ;
WILLETT, WC ;
MANSON, JE ;
STAMPFER, MJ ;
HENNEKENS, C ;
ROSNER, B ;
SPEIZER, FE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) :1589-1593
[4]   Targeted for drug delivery [J].
Fahmy, Tarek M. ;
Fong, Peter M. ;
Goyal, Amit ;
Saltzman, W. Mark .
MATERIALS TODAY, 2005, 8 (08) :18-26
[5]  
FLEISCH H, 1978, METAB BONE DIS RELAT, V54, P265
[6]   Prostaglandin E2-bisphosphonate conjugates:: Potential agents for treatment of osteoporosis [J].
Gil, L ;
Han, YX ;
Opas, EE ;
Rodan, GA ;
Ruel, R ;
Seedor, JG ;
Tyler, PC ;
Young, RN .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (05) :901-919
[7]   Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona [J].
Heald, CR ;
Stolnik, S ;
Kujawinski, KS ;
De Matteis, C ;
Garnett, MC ;
Illum, L ;
Davis, SS ;
Purkiss, SC ;
Barlow, RJ ;
Gellert, PR .
LANGMUIR, 2002, 18 (09) :3669-3675
[8]   Bone-specific drug delivery systems - Approaches via chemical modification of bone-seeking agents [J].
Hirabayashi, H ;
Fujisaki, J .
CLINICAL PHARMACOKINETICS, 2003, 42 (15) :1319-1330
[9]   Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS) [J].
Hirabayashi, H ;
Takahashi, T ;
Fujisaki, J ;
Masunaga, T ;
Sato, S ;
Hiroi, J ;
Tokunaga, Y ;
Kimura, S ;
Hata, T .
JOURNAL OF CONTROLLED RELEASE, 2001, 70 (1-2) :183-191
[10]   Selective drug delivery system to bone:: Small peptide (Asp)6 conjugation [J].
Kasugai, S ;
Fujisawa, R ;
Waki, Y ;
Miyamoto, K ;
Ohya, K .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (05) :936-943